Prenetics (PRE) Q3 2026 earnings review
Prenetics grows supplement sales fast, but its loss plan triples
Prenetics is growing its IM8 supplement brand rapidly, but management tripled its second-half loss plan to keep buying new customers. Third-quarter revenue rose 38% from last quarter to $64 million, slightly above its target, as active subscriptions reached 160,000. However, chief executive Danny Yeung widened the second-half operating loss plan excluding one-offs to $30 million to $35 million, while keeping the full-year sales outlook unchanged.
| IM8 brand revenue | $62.9M +40% from last quarter; +266% from a year ago |
|---|---|
| Early 2025 cohort return | 4.1x gross profit collected per $1 of marketing cost |
| Second-half operating loss outlook | Cut to $(30)–(35)M from $(8)–(12)M expected in August |
| Full-year total revenue outlook | Unchanged $220–230M ($400M+ IM8 in 2027) |
⚖️ Verdict: ⚪ Neutral
The story is unchanged because stronger proof of customer loyalty was offset by a deeper operating loss and another product delay. Billing records now show the first 27,000 customers returned 4.1 times their marketing cost in gross profit, which eases doubts about repeat buying. The bad news: standard operating cash outflow doubled to $28 million—covered by marketing loans—and the Hydration drink launch slipped into early 2027.
The question now is whether customers acquired this year at nearly $300 each will stay as long as early buyers who cost $104. If they keep renewing their three-month plans, repeat orders will shrink the marketing bill as a share of sales; if they cancel early, the company will be left repaying its marketing loan facility from a slower base. Fourth-quarter renewals from September's record customer group will tell.
🐂 Bull Case
Early Subscribers Returned Four Times Their Marketing Cost
Prenetics runs IM8, a direct-to-consumer nutrition brand selling daily supplement powders and longevity capsules. Its business model relies on subscribers staying long enough to pay back their upfront marketing cost, though bears worry that newer customers on three-month plans will cancel faster. Chief executive Danny Yeung countered that concern with updated billing records across every customer group since launch.
- First full-quarter customer group (27,000 buyers from early 2025): returned 4.1 times their marketing cost in gross profit
- All customer groups through March 2026: returned $1.68 in gross profit per marketing dollar, up from $1.52 last quarter
- Active subscriptions: reached about 160,000 at September month-end, up from 140,000 in July
- Repeat orders: generated $37.5 million, or 59% of direct customer billings in the third quarter
These figures matter because they reflect cash already collected rather than long-term projections. Independent U.S. card data from Indagari also showed 11.0% of first-time IM8 buyers still ordering after 22 months, ahead of rival brands Thorne at 8.7% and AG1 at 8.5%. In addition, customers acquired in January 2026 at a $284 marketing cost paid back that expense in gross profit within six months.
What to watch: second-renewal retention rates for the 52,696 customers acquired in September, 43% of whom bought three-month plans that bill again in December. Strong December renewals would confirm that the larger 2026 customer groups behave like the early 2025 buyers.
Revenue Growth Cut Overhead and Marketing Ratios
Fast revenue growth is beginning to shrink the company's fixed overhead burden. Total revenue rose 38% from last quarter to $64.1 million, while the IM8 team kept headcount near 70 employees by using artificial intelligence software to produce and test thousands of digital advertisements. As a result, operating loss before interest, tax and one-offs narrowed from 39% of revenue in the second quarter to 20% in the third.
Three expense lines drove that 19-percentage-point margin improvement. Day-to-day operating costs—covering staff, payments and research—fell from 25% of revenue in the first quarter to 16% in the third. Brand royalties and ambassador fees dropped 4 percentage points from last quarter to 5% of revenue because David Beckham's royalty rate stepped down from 5.0% to 3.5% after cumulative sales passed $100 million. Meanwhile, customer acquisition marketing fell 16 percentage points to 62% of revenue even though dollar spending rose 10% to $40.0 million.
What to watch: day-to-day operating costs as a share of revenue in the fourth quarter, when management plans to add 25 to 30 staff over the coming year. Holding that ratio near 16% would show the business can enter new product categories without rebuilding a heavy corporate cost base.
🐻 Bear Case
Management Tripled Its Second-Half Loss Plan
"Returns like these are why we now expect a second-half Adjusted EBITDA loss of $30 to $35 million. That is our choice," chief executive Danny Yeung said. Back in August, management set that second-half operating loss target at $8 million to $12 million, after starting the year with a full-year loss target of $16 million to $20 million. By our math, the new outlook puts the full-year operating loss excluding one-offs at about $58 million, nearly triple the original plan.
The company cut its profit outlook to spend more on customer acquisition in the third and fourth quarters, yet it did not raise its full-year revenue outlook of $220 million to $230 million or its 2027 IM8 sales target of $400 million or more. Finance chief designate Brian Rosin told analysts that third-quarter marketing filled the awareness funnel and that management preferred to keep a wide revenue range rather than set the bar too high. Spending an extra $22.5 million on second-half marketing without lifting the revenue target means each marketing dollar is producing less immediate revenue than August's plan assumed.
What to watch: fourth-quarter IM8 revenue against the $73 million to $80 million implied by the full-year outlook. Landing near the bottom of that range after tripling the second-half loss budget would show diminishing returns on ad spending.
Borrowing Covers the Growing Operating Cash Drain
Prenetics highlighted positive $4.1 million of Adjusted Free Cash Flow, a custom liquidity measure that adds marketing loan proceeds to operating cash flow. Supporters view the $1 billion General Catalyst facility, which funds up to 70% of qualifying marketing spend in exchange for a capped 1.17-times return from customer receipts, as non-dilutive validation of the business model. However, the press release notes that the custom cash metric "is not a measure of cash generated from operations".
Under standard accounting rules, net cash used in operating activities doubled to $27.5 million in the third quarter from $13.7 million in the second quarter. The health group paid for $40.0 million of acquisition marketing and spent $15.5 million building inventory and supplier deposits, then plugged the gap with $31.6 million of net borrowings from General Catalyst ($39.2 million drawn minus $7.6 million repaid). That left $34.7 million of facility borrowings on the September balance sheet and generated $0.8 million of finance charges.
What to watch: standard operating cash flow and General Catalyst repayment volumes in the first half of 2027. Rosin noted that monthly loan draws will exceed repayments for about 18 months, meaning the liability on the balance sheet will keep climbing before the facility turns cash-neutral.
Customer Acquisition Costs Rose in Late Summer
Management emphasized that IM8's Customer Acquisition Cost (CAC), the average marketing spend needed to win one new buyer, fell for a second straight quarter from $305 in the first quarter and $301 in the second to $285 in the third. That quarterly drop helped IM8 bring in a record 137,892 new customers on $39.3 million of brand marketing spend.
However, the quarterly average hides a sharp jump late in the summer and a much higher cost than a year ago. After spending $239 per customer in July to win 47,373 buyers, IM8 raised monthly ad spending to $14 million in August and September, pushing the average acquisition cost across those two months up to about $310. Compared with the third quarter of 2025, when acquiring a customer cost $122 against a $114 first order, the third-quarter acquisition cost is up 134% while the average first order is up 82% to $207.
What to watch: fourth-quarter Customer Acquisition Cost, which Yeung said should fluctuate within 10% to 15% of the $300 mark during holiday ad auctions. A rise above $330 without a higher average order value would lengthen the six-month payback period.
Product Launches Slipped Into Next Year
Prenetics is building a clinical testing moat and a broader product lineup to turn IM8 into a multi-product household brand. Three randomized, placebo-controlled clinical studies—covering gut health, longevity, and a 100-worker study at Mayo Clinic in Florida—remain underway, and the company signed a 10-year global licensing deal for Care Bears gummy vitamins and an Asian sponsorship with the NBA. Yet none of the new products promised for late 2026 will arrive this year.
In the first quarter, management planned to launch IM8 Hydration, Creatine and kids' gummies in the fourth quarter of 2026; in August, it staggered gummies and creatine into 2027 while keeping Hydration in the fourth quarter. Now Yeung has pushed IM8 Hydration into the first quarter of 2027 as well: "We moved it on purpose: the Black Friday week buries a new product’s story under a wall of discounts". Care Bears gummies are scheduled for the first half of 2027, retail and China entries are set for late 2027, and the two registered clinical trials do not report until the end of the first quarter.
What to watch: commercial availability of IM8 Hydration and the clinical readouts for the longevity and gut health studies by March 31, 2027. Any further delay would slow the plan to cross-sell second products to existing subscribers at zero marketing cost.
Risks this quarter didn't answer
Two standing structural risks saw no resolution in the third-quarter materials and remain open ahead of 2027.
- Celebrity and brand concentration: IM8 relies heavily on co-founder David Beckham and eight equity-holding celebrity ambassadors (adding actress Lily Collins and musician Diplo this quarter); contractual royalties and ambassador fees cost $3.3 million in Q3, and any reputational issue would test demand.
- Warrant and equity overhang: roughly 2.36 million Class C warrants at an $18.00 strike price and 724,452 Class A and B warrants remain outstanding alongside unquantified equity grants to new ambassadors and licensing partner Authentic Brands Group; full warrant disclosure in the annual Form 20-F will show total potential dilution.
👓 Other Themes
Affluent Buyer Base Cushions Economic Pressure
Macroeconomic consumer pressure has not slowed demand for IM8's $89-to-$208 monthly regimens because its buyers skew wealthy. Independent card panel data shows 52% of IM8 customers earn over $150,000 a year, 10 percentage points higher than peers Thorne, AG1 and Grüns. With 48% of sales in the United States and 52% across 45 other countries, the company also added a new contract manufacturer starting in early 2027 to lower production and shipping costs.
💲 Other KPIs
Consolidated gross margin dipped 1.5 percentage points from 65.0% in the second quarter, while IM8's brand gross margin slipped from 65% to 63%. A one-time $1.3 million write-off of older Daily Ultimate Essentials powder after a product reformulation cost about 2 percentage points of margin; by our math, underlying IM8 gross margin held steady at 65.5%.
Ending inventory jumped 43.4% from last quarter to $20.1 million, up from $14.0 million in June and $7.0 million at year-end 2025. Prenetics also held $9.8 million in supplier deposits inside its $28.3 million prepayments line. Management built stock ahead of fourth-quarter holiday renewals and the first-quarter launch of IM8 Hydration, absorbing $15.5 million of operating cash.
Weighted average basic and diluted shares rose 25.8% from a year ago (13.90 million) and 1.2% from the second quarter (17.27 million), as late-2025 equity placements outweighed the $40 million share buyback completed in the first half. Rising share prices also triggered a $7.2 million non-cash accounting charge on warrant liabilities, widening the reported net loss to $25.4 million.
🔮 Guidance
Unchanged. The full-year plan still calls for total sales to more than double to $225 million at the middle of the range. By our math, subtracting nine-month sales of $146.6 million leaves $73.4 million to $83.4 million for the fourth quarter, or 22.4% growth from the third quarter at the middle of the range, down from 37.9% sequential growth in the third quarter.
Unchanged. After raising the IM8 target by $10 million in the first quarter and $18.5 million in the second, management kept the middle of the range at $218.5 million. By our math, that leaves $73.3 million to $80.3 million for the fourth quarter, or 22.0% sequential growth at the middle of the range, supported by December renewals from September's three-month subscribers.
Cut. The health group widened its expected second-half operating loss excluding one-offs by $22.5 million at the middle of the range to fund extra customer acquisition. With a $12.7 million loss recorded in the third quarter, by our math the plan leaves a $17.3 million to $22.3 million loss for the fourth quarter, widening the loss margin from 20% of sales to about 25%.
Unchanged. The target requires December monthly IM8 revenue to reach at least $25.0 million, up from $23.7 million in September ($284 million annualized). Because 43% of September's record 52,696 new customers selected three-month plans that bill their full three-month value upon shipment in December, normal renewal activity makes the year-end run-rate target achievable.
Unchanged. Management kept its 2027 floor at $400 million, representing at least 83% growth over the 2026 IM8 outlook midpoint. The company projects that customers acquired through the end of 2026 plus online marketplaces will generate $175 million of that total, leaving $225 million to come from new 2027 buyers, with zero revenue included from Hydration, Care Bears, retail or China.
Unchanged. The company expects its custom liquidity measure to stay above zero in the fourth quarter and beyond. Because fourth-quarter operating loss excluding one-offs is planned at $17 million to $22 million, standard operating cash flow will remain negative while net loan draws from the General Catalyst marketing facility cover up to 70% of customer acquisition spending.
❓ Key Questions
Why did extra second-half marketing not lift the revenue plan?
Management increased its second-half operating loss budget by $22.5 million to buy more ads, yet kept its 2026 and 2027 revenue targets unchanged. Investors need to know how many fourth-quarter customer additions that extra spending buys and why their orders do not raise 2027 sales.
How do 2026 three-month subscribers renew at month six?
The $1.68 gross profit return per marketing dollar blends early 2025 monthly buyers with newer 2026 three-month buyers. Disclosing second-cycle (month-six) renewal rates specifically for the first-quarter and second-quarter 2026 three-month cohorts would show whether paying $328 upfront causes higher cancellations later.
How many shares were granted to Authentic Brands and ambassadors?
Prenetics signed licensing partner Authentic Brands Group and celebrities Lily Collins and Diplo as strategic shareholders this quarter. Management has not disclosed the exact number of shares or warrants issued for these deals or how they affect fully diluted share count.
What are the upfront slotting and working-capital costs for retail?
Chief executive Danny Yeung is negotiating with a major U.S. big-box retailer to put Hydration and Care Bears gummies on shelves by late 2027. Retail rollouts require inventory consignment, slotting fees and longer receivable terms that the General Catalyst marketing facility does not fund.
